Vimarsana
Biggest News Aggregation in the World

Renato Lopes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Renato Lopes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Renato Lopes Today - Breaking & Trending Today

Major trial finds apixaban reduces stroke risk in patients with device-detected atrial fibrillation - Vimarsana News

Major trial finds apixaban reduces stroke risk in patients with device-detected atrial fibrillation

The widely available blood thinner apixaban substantially reduced stroke in at-risk patients with a type of atrial fibrillation only detectable by a pacemaker or other implanted cardiac electronic device, a global study has found.

No Aspirin After PCI? Extended P2Y12 Monotherapy? Trials Weigh In - Vimarsana News

No Aspirin After PCI? Extended P2Y12 Monotherapy? Trials Weigh In

Two trials read out, but generalizability is the question

Q&A: Climatologist Carlos Nobre's dream of an Amazon Institute of Technology - Vimarsana News

Q&A: Climatologist Carlos Nobre's dream of an Amazon Institute of Technology

His goal is to transform the heart of the Amazon into a cutting-edge science production hub by connecting technical expertise and Native peoples’ knowledge. If he were not the project’s mastermind, this effort would sound impossible in a region that is increasingly degraded and taken over by environmental crime. But Carlos Nobre — one of […]

No Benefit of Rivaroxaban in COVID Outpatients: PREVENT-HD - Vimarsana News

No Benefit of Rivaroxaban in COVID Outpatients: PREVENT-HD

PREVENT-HD is the largest randomized study to look at anticoagulation in nonhospitalized COVID-19 patients and joins a long list of smaller trials also showing no benefit with this approach.

Anticoagulation Again Flops for Outpatient COVID-19 - Vimarsana News

Anticoagulation Again Flops for Outpatient COVID-19

Largest-yet RCT shows no benefit for non-hospitalized symptomatic patients despite elevated risk